ClinicalTrials.gg
CompletedNCT01022762Updated Jul 9, 2014Results posted

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

A Phase 4 interventional study of repaglinide and gliclazide in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing repaglinide in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. repaglinide · Diabetes Mellitus, Type 2.

Enrollment
2nd of 22
440 · median 101
Started
2009
with 2 others
Phase 4
15 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
12 of 22
Novo Nordisk A/S

Among the 22 studies testing repaglinide in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 3 that started in 2009, is one of 15 in phase 4, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 22 studies testing repaglinide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About repaglinide

repaglinide: first FDA approval 1997 (PRANDIN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing repaglinide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 440 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Oral anti-diabetic drug (OAD) naïve (unsystematic OAD treatment 6 months prior to this trial is allowed)
  • Insulin naïve (less than 1 week of daily use of insulin therapy before trial start is allowed)
  • Lipid-lowing agent naïve
  • : 6.5-8.5%
  • Fasting glucose: 6.1-13.0 mmol/L (110-234 mg/dl)
  • (BMI): 20-35 kg/m\^2
  • Be able and willing to perform self-monitored plasma glucose (SMPG)
  • Be able and willing to eat 3 main meals per day
  • Only applicable to subjects who will participate in the subgroup study: Be able and willing to perform and complete IVGTT (intravenous glucose tolerance test) at additional visits

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to repaglinide, gliclazide, or related products (for example sulfonamide or other sulphonylureas (SUs)), or any of the in the study drugs
  • Previous participation in this study
  • Participation in a study of another drug within 1 month prior to study start
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (actual)

Study arms

  • Active comparator
    repaglinide

    1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily

    Drug: repaglinide

  • Active comparator
    gliclazide

    80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily

    Drug: gliclazide

Interventions

  • Individually adjusted dose for 16 weeks

  • Individually adjusted dose for 16 weeks

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Time frame: Week 0, week 16

Secondary outcomes

  1. Change in Fasting Plasma Glucose

    Time frame: Week 0, week 16

  2. Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal

    A standard meal contains 100g carbohydrate

    Time frame: Week 0, week 16

  3. Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%

    Time frame: Week 16

  4. Change in Fasting Serum Free Fatty Acid (FFA) From Baseline

    Time frame: Week 0, week 16

  5. Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal

    Time frame: Week 0, week 16

  6. Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)

    Time frame: Over the course of three hours at Week 0 and Week 16

  7. Change in AUC0-180 of Plasma Glucose Concentration of IVGTT

    Time frame: Over the course of three hours at Week 0 and Week 16

  8. Number of All Treatment Emergent Hypoglycaemic Episodes

    A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.

    Time frame: Weeks 0-16

  9. Cholesterol

    The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.

    Time frame: Week 0, week 16

  10. Change in Body Weight

    Time frame: Week 0, week 16

08

Results

Posted Dec 29, 2011

Participant flow

The trial was conducted at 23 sites in China.

Participant flow — Overall Study
MilestoneRepaglinideGliclazide
Started218222
Exposed to trial drug217218
Completed196194
Not completed2228
Withdrew: Adverse event31
Withdrew: Lack of efficacy01
Withdrew: Protocol violation76
Withdrew: Unclassified1220

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)
Time frame:
Week 0, week 16
Reported as:
Least squares mean · percentage (%) of total haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage (%) of total haemoglobinRepaglinideGliclazide
Change in Glycosylated Haemoglobin (HbA1c)-0.857 ± 0.051-0.871 ± 0.051
Statistical analysis
  • Repaglinide vs Gliclazide · ANCOVA · Mean difference (net): 0.014 · 95% CI -0.115 to 0.143If non-inferiority of repaglinide alone was shown, a test for superiority would be performed based on FAS. Superiority of repaglinide alone over gliclazide alone would be claimed if the upper limit of the 95% CI for the difference was lower than 0%.
SecondaryChange in Fasting Plasma Glucose
Time frame:
Week 0, week 16
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose
mmol/LRepaglinideGliclazide
Change in Fasting Plasma Glucose-1.409 ± 0.104-1.667 ± 0.102
SecondaryChange in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal

A standard meal contains 100g carbohydrate

Time frame:
Week 0, week 16
Reported as:
Least squares mean · mmol/L
Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal
mmol/LRepaglinideGliclazide
Change in 2-hour Postprandial Plasma Glucose (PPG) Over a Standard Meal-0.596 ± 0.215-0.699 ± 0.211
SecondaryPercentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%
Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%
percentage of participantsRepaglinideGliclazide
Percentage of Participants Achieving the Treatment Target of HbA1c Below or Equal to 6.5%6259
SecondaryChange in Fasting Serum Free Fatty Acid (FFA) From Baseline
Time frame:
Week 0, week 16
Reported as:
Least squares mean · mmol/L
Change in Fasting Serum Free Fatty Acid (FFA) From Baseline
mmol/LRepaglinideGliclazide
Change in Fasting Serum Free Fatty Acid (FFA) From Baseline-0.012 ± 0.014-0.02 ± 0.014
SecondaryChange in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal
Time frame:
Week 0, week 16
Reported as:
Least squares mean · mmol/L
Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal
mmol/LRepaglinideGliclazide
Change in 2-hour Postprandial Serum Free Fatty Acid (FFA) Over a Standard Meal-0.003 ± 0.007-0.004 ± 0.007
SecondaryChange in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)
Time frame:
Over the course of three hours at Week 0 and Week 16
Reported as:
Mean · min*pmol/L
Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)
min*pmol/LRepaglinideGliclazide
Change in AUC0-180 of Serum Insulin Concentration of IVGTT (Intravenous Glucose Tolerance Test)5139.55 ± 8720.801426.21 ± 5262.15
SecondaryChange in AUC0-180 of Plasma Glucose Concentration of IVGTT
Time frame:
Over the course of three hours at Week 0 and Week 16
Reported as:
Mean · min*mmol/L
Change in AUC0-180 of Plasma Glucose Concentration of IVGTT
min*mmol/LRepaglinideGliclazide
Change in AUC0-180 of Plasma Glucose Concentration of IVGTT-272.30 ± 290.79-348.03 ± 258.86
SecondaryNumber of All Treatment Emergent Hypoglycaemic Episodes

A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of trial product and no later than the last day of the trial product.

Time frame:
Weeks 0-16
Reported as:
Number · episodes
Number of All Treatment Emergent Hypoglycaemic Episodes
episodesRepaglinideGliclazide
Number of All Treatment Emergent Hypoglycaemic Episodes165147
SecondaryCholesterol

The number of participants having a change in cholesterol from "normal" to "abnormal". "Abnormal" means a value of blood cholesterol is out of the normal range.

Time frame:
Week 0, week 16
Reported as:
Number · participants
Cholesterol
participantsRepaglinideGliclazide
Cholesterol1811
SecondaryChange in Body Weight
Time frame:
Week 0, week 16
Reported as:
Least squares mean · kg
Change in Body Weight
kgRepaglinideGliclazide
Change in Body Weight-0.750 ± 0.218-0.511 ± 0.215

Adverse events

Collected over The adverse events were collected in a timespan of 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Repaglinide—3/216 (1.4%)0/216 (0%)
Gliclazide—0/219 (0%)0/219 (0%)
Most frequent serious events
Most frequent serious events
EventRepaglinideGliclazide
Haemorrhoidal haemorrhageGastrointestinal disorders1/2160/219
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders1/2160/219
Gall bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2160/219

Baseline characteristics

Age, Continuous
Age, Continuous(years)RepaglinideGliclazideTotal
Mean54.1 ± 10.053.5 ± 9.953.8 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)RepaglinideGliclazideTotal
Female10795202
Male110123233
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RepaglinideGliclazideTotal
Hispanic or Latino000
Not Hispanic or Latino217218435
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RepaglinideGliclazideTotal
American Indian or Alaska Native000
Asian217218435
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)RepaglinideGliclazideTotal
China217218435
Height
Height(cm)RepaglinideGliclazideTotal
Mean163.2 ± 8.9163.9 ± 8.4163.5 ± 8.7
Weight
Weight(kg)RepaglinideGliclazideTotal
Mean68.7 ± 11.668.4 ± 11.268.6 ± 11.4
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)RepaglinideGliclazideTotal
Mean25.69 ± 3.0025.37 ± 3.0125.53 ± 3.00

1 further baseline measures are reported on the registry.

09

Study locations

1 site
  • Shanghai, Shanghai 200025, China
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2009
First posted
Dec 1, 2009
Start
Nov 2009
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Dec 29, 2011
Last update
Jul 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01022762
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 1, 2009
Start date
Nov 2009
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Dec 29, 2011
Last update
Jul 9, 2014

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Gliclazide

Start the discussion